Advertisement

Journal of Neuro-Oncology

, Volume 140, Issue 2, pp 249–260 | Cite as

Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes

  • Zixuan Yuan
  • Liang Zhao
  • Yafei Zhang
  • Shun Li
  • Bomin Pan
  • Lei Hua
  • Zhen Wang
  • Chengkun Ye
  • Jun Lu
  • Rutong Yu
  • Hongmei Liu
Laboratory Investigation

Abstract

Purpose

GOLPH3 has been shown to be involved in glioma proliferation. In this study, we aimed to demonstrate that GOLPH3 can serve as a target for glioma gene therapy.

Methods

During the experiment, cationic liposomes with angiopep-2 (A2-CL) were used to deliver siGOLPH3 crossing the blood–brain barrier and reaching the glioma.

Results

At the cellular level, the A2-CL/siGOLPH3 could silence GOLPH3 and then effectively inhibited the proliferation of cells. In vivo experiments, using U87-GFP-Luci-bearing BALB/c mouse models, we demonstrated that A2-CL could deliver GOLPH3-siRNA specifically to glioma and effectively inhibit glioma growth.

Conclusions

This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications.

Keywords

Glioma GOLPH3 RNAi Angiopep-2 Liposome 

Notes

Acknowledgements

This work was financially supported by National Natural Science Foundation of China (Grants No. 81772665, 81502153, 81472345, 81302175), Natural Science Foundation of Jiangsu Province (Grants No. BK20150221), China Postdoctoral Science Foundation funded project (Grants No. 2016M591926; 2017T100409), Jiangsu Province, Key Research & Development Plan of Jiangsu Province (No. BE2016646), Jiangsu provincial Commission of Health and Family Planning (Grants No. Q201608), Jiangsu Provincial Medical Youth Talent (QNRC2016786), and Postgraduate Research & Practice Innovation Program of Jiangsu Province (Grants No. SJCX17_0551).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human or animal rights

This article does not contain any studies with human participants performed by any of the authors. This article contains studies with animals performed by authors and all applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

References

  1. 1.
    Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507CrossRefGoogle Scholar
  2. 2.
    Sukhdeo K, Hambardzumyan D, Rich JN (2011) Glioma development: where did it all go wrong? Cell 146:187–188CrossRefGoogle Scholar
  3. 3.
    Jain RK, Di TE, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefGoogle Scholar
  4. 4.
    Bumcrot D, Manoharan M, Koteliansky V, Sah DWY (2006) RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2:711–719CrossRefGoogle Scholar
  5. 5.
    Rietwyk S, Peer D (2017) Next-generation lipids in RNA interference therapeutics. ACS Nano 11:7572–7586CrossRefGoogle Scholar
  6. 6.
    Dowdy SF (2017) Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol 35:222–229CrossRefGoogle Scholar
  7. 7.
    Cohen ZR, Ramishetti S, Peshesyaloz N, Goldsmith M, Wohl A, Zibly Z, Peer D (2015) Localized RNAi therapeutics of chemo-resistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9:1581–1591CrossRefGoogle Scholar
  8. 8.
    Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X (2012) Overexpression of golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol 110:195–203CrossRefGoogle Scholar
  9. 9.
    Buschman MD, Rahajeng J, Field SJ (2015) GOLPH3 links the golgi, DNA damage, and cancer. Can Res 75:624–627CrossRefGoogle Scholar
  10. 10.
    Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459:1085–1090CrossRefGoogle Scholar
  11. 11.
    Zhou X, Xie S, Wu S, Qi Y, Wang Z, Zhang H, Dong L, Wang X, Yu D, Liu G (2017) Golgi phosphoprotein 3 promotes glioma progression via inhibiting Rab5-mediated endocytosis and degradation of epidermal growth factor receptor. Neuro Oncol 19(12):1628–1639CrossRefGoogle Scholar
  12. 12.
    Boado RJ (2007) Blood–brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 24:1772–1787CrossRefGoogle Scholar
  13. 13.
    Podesta JE, Al-Jamal KT, Herrero MA, Tian B, Ali-Boucetta H, Hegde V, Bianco A, Prato M, Kostarelos K (2010) Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 5:1176–1185Google Scholar
  14. 14.
    Lv H, Zhang S, Wang B, Cui S, Yan J (2006) Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114:100–109CrossRefGoogle Scholar
  15. 15.
    Oller-Salvia B, Sanchez-Navarro M, Giralt E, Teixido M (2016) ChemInform abstract: blood—brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chem Soc Rev 47:4690–4707CrossRefGoogle Scholar
  16. 16.
    Cho CF, Wolfe JM, Fadzen CM, Calligaris D, Hornburg K, Chiocca EA, Agar NYR, Pentelute BL, Lawler SE (2017) Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents. Nat Commun 8:15623CrossRefGoogle Scholar
  17. 17.
    Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR (2014) Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35:5226–5239CrossRefGoogle Scholar
  18. 18.
    Mckinley KL, Cheeseman IM (2014) Polo-like kinase 1 licenses CENP-A deposition at centromeres. Cell 158:397–411CrossRefGoogle Scholar
  19. 19.
    Gao H, Zhang S, Cao S, Yang Z, Pang Z, Jiang X (2014) Angiopep-2 and activatable cell-penetrating peptide dual-functionalized nanoparticles for systemic glioma-targeting delivery. Mol Pharm 11:2755–2763CrossRefGoogle Scholar
  20. 20.
    Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DWY, Stebbing D, Crosley EJ, Yaworski E (2010) Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28:172–176CrossRefGoogle Scholar
  21. 21.
    Liu H, Qiao C, Yang J, Weng J, Zhang X (2014) Self-assembling doxorubicin-prodrug nanoparticles as siRNA drug delivery system for cancer treatment: in vitro and in vivo. J Mater Chem B 2:5910–5924CrossRefGoogle Scholar
  22. 22.
    Shukla A, Dong K, Sharma M, Magidson V, Loncarek J (2015) Plk1 relieves centriole block to reduplication by promoting daughter centriole maturation. Nat Commun 6:8077CrossRefGoogle Scholar
  23. 23.
    Zhou X, Zhan W, Bian W, Hua L, Shi Q, Xie S, Yang D, Li Y, Zhang X, Liu G (2013) GOLPH3 regulates the migration and invasion of glioma cells though RhoA. Biochem Biophys Res Commun 433:338–344CrossRefGoogle Scholar
  24. 24.
    Zhang X, Ding Z, Mo J, Sang B, Shi Q, Hu J, Xie S, Zhan W, Lu D, Yang M (2015) GOLPH3 promotes glioblastoma cell migration and invasion via the mTOR-YB1 pathway in vitro. Mol Carcinog 54:1252–1263CrossRefGoogle Scholar
  25. 25.
    Abbott N, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41–53CrossRefGoogle Scholar
  26. 26.
    Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612CrossRefGoogle Scholar
  27. 27.
    Miller TE, Liau BB, Wallace LC, Morton AR, Qi X, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q (2017) Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature 547:355–359CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Nervous System DiseasesXuzhou Medical UniversityXuzhouPeople’s Republic of China
  2. 2.Brain HospitalAffiliated Hospital of Xuzhou Medical UniversityXuzhouPeople’s Republic of China
  3. 3.Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life ScienceJiangsu Normal UniversityXuzhouPeople’s Republic of China
  4. 4.General Hospital of Xuzhou Mining GroupXuzhouPeople’s Republic of China

Personalised recommendations